AI-Supported Breast Cancer Screening - New Results Suggest Even Higher Accuracy

The new findings are published in The Lancet Digital Health. The initial results of the Mammography Screening with Artificial Intelligence (MASAI) study* - a randomised trial to evaluate whether AI can improve mammography screening - were published in August 2023. The study started in spring 2021, and the final report will be written next year. A second report has now been published, and Kristina Lång, who is responsible for the study, is pleased to be able to show strong figures.

"Since the first report last year, the number of cancers detected by AI-supported screening has gone from being 20 per cent more to 29 per cent more than those found by traditional screening," says Kristina Lång, researcher and associate professor of diagnostic radiology at Lund University, Sweden and consultant at the Unilabs Mammography Unit in Malmö.

Every year, around one million women are called for mammography screening in Sweden. The mammogram are reviewed by two breast radiologists - a medical skill that is currently in short supply. In the MASAI trial, AI had to identify mammograms with an increased risk of breast cancer. These cases were then reviewed by two breast radiologists. Other mammograms were only reviewed by one breast radiologist. In all these cases, the radiologist(s) was/were assisted by AI, which highlighted suspicious findings on the image.

The new research report is based on results from almost 106,000 women screened for breast cancer. Half of them were randomly assigned to undergo traditional mammography screening, while the other half received AI-supported screening. AI-supported screening was found to pick up not only more cancers overall (in 338 people compared with 262) but also 24 per cent more early-stage invasive cancers (in 270 people compared with 217).

"They also included relatively more aggressive cancers that are particularly important to detect early. At a later stage, the prognosis may have deteriorated and more intensive treatment is often required," says Kristina Lång, pointing to potential benefits in terms of reduced suffering, higher survival rates and lower economic costs if these cancers can be detected more frequently at an early stage.

Pre-cancerous lesions, known as in situ cancers, were also more likely to be detected with AI - 51 per cent more such cases were found (68 people compared with 45). A large proportion of the additional in situ cases found were of the more severe type which also benefits from early detection.

Importantly in this context, the number of false positives did not rise despite an increase in cancer detection.

"A false positive is when a woman is recalled for work up but is then found not to have cancer. This can be a stressful experience for women participating in screening. But only seven more people, corresponding to a one per cent increase, received these false alarms in the AI-supported group compared with the control group," says Kristina Lång.

As in the previous report from last year, AI-supported screening was again found to significantly reduce breast radiologists’ workload by 44 per cent.

Sweden has a generous screening programme by international standards. All women aged 40-74 years are invited for a mammogram every 1.5-2 years. However, the interval between two screening visits can be long enough for cancer to be diagnosed - even if the last screening was considered normal. These so called interval cancers is the next group of cancers that Kristina Lång and her colleagues will analyse.

"This December, the 106,000 women have been followed up for two years, allowing researchers to see how common it is to receive a breast cancer diagnosis between two screening visits. Our hope is that AI will prove helpful here too," says Kristina Lång.

Results from the MASAI trial have already contributed to the implementation of AI support in several regional screening programs in Sweden.

Hernström V, Josefsson V, Sartor H, Schmidt D, Larsson AM, Hofvind S, Andersson I, Rosso A, Hagberg O, Lång K.
Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study.
Lancet Digit Health. 2025 Feb 3:S2589-7500(24)00267-X. doi: 10.1016/S2589-7500(24)00267-X

* The MASAI trial has been funded with support from the Swedish Cancer Society, Lund University/ALF, the Confederation of Regional Cancer Centres and MAS Cancer.

Most Popular Now

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...

AI Medical Receptionist Modernizing Doct…

A virtual medical receptionist named "Cassie," developed through research at Texas A&M University, is transforming the way patients interact with health care providers. Cassie is a digital-human assistant created by Humanate...

Using Data and AI to Create Better Healt…

Academic medical centers could transform patient care by adopting principles from learning health systems principles, according to researchers from Weill Cornell Medicine and the University of California, San Diego. In...

AI Tool Set to Transform Characterisatio…

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within...

AI Detects Hidden Heart Disease Using Ex…

Mass General Brigham researchers have developed a new AI tool in collaboration with the United States Department of Veterans Affairs (VA) to probe through previously collected CT scans and identify...

Highland Marketing Announced as Official…

Highland Marketing has been named, for the second year running, the official communications partner for HETT Show 2025, the UK's leading digital health conference and exhibition. Taking place 7-8 October...

Human-AI Collectives Make the Most Accur…

Diagnostic errors are among the most serious problems in everyday medical practice. AI systems - especially large language models (LLMs) like ChatGPT-4, Gemini, or Claude 3 - offer new ways...

MHP-Net: A Revolutionary AI Model for Ac…

Liver cancer is the sixth most common cancer globally and a leading cause of cancer-related deaths. Accurate segmentation of liver tumors is a crucial step for the management of the...